-
Ab176451-10mgKWAR23 (anti-SIRPg) is a recombinant human antibody that act againts anti-SIRPG (anti-Signal-Regulatory Protein Gamma).Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
-
Ab176451-1mgKWAR23 (anti-SIRPg) is a recombinant human antibody that act againts anti-SIRPG (anti-Signal-Regulatory Protein Gamma).Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
-
Ab176451-5mgKWAR23 (anti-SIRPg) is a recombinant human antibody that act againts anti-SIRPG (anti-Signal-Regulatory Protein Gamma).Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
-
Ab176216-100μgLadiratuzumab (anti-SLC39A6) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab (anti-SLC39A6), conjugated with the microtubule disrupting agent, MMAE to compose SGN-LIV1A, an antibody-drug conjugate (ADC). Ladiratuzumab
-
Ab176216-10mgLadiratuzumab (anti-SLC39A6) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab (anti-SLC39A6), conjugated with the microtubule disrupting agent, MMAE to compose SGN-LIV1A, an antibody-drug conjugate (ADC). Ladiratuzumab
-
Ab176216-1mgLadiratuzumab (anti-SLC39A6) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab (anti-SLC39A6), conjugated with the microtubule disrupting agent, MMAE to compose SGN-LIV1A, an antibody-drug conjugate (ADC). Ladiratuzumab
-
Ab176216-5mgLadiratuzumab (anti-SLC39A6) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab (anti-SLC39A6), conjugated with the microtubule disrupting agent, MMAE to compose SGN-LIV1A, an antibody-drug conjugate (ADC). Ladiratuzumab
-
Ab176092-100μgLexatumumab (anti-TNFRSF10B) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab (anti-TNFRSF10B) induces apoptosis in malignant mesothelioma. Lexatumumab (anti-TNFRSF10B) can be used for
-
Ab176092-10mgLexatumumab (anti-TNFRSF10B) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab (anti-TNFRSF10B) induces apoptosis in malignant mesothelioma. Lexatumumab (anti-TNFRSF10B) can be used for
-
Ab176092-1mgLexatumumab (anti-TNFRSF10B) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab (anti-TNFRSF10B) induces apoptosis in malignant mesothelioma. Lexatumumab (anti-TNFRSF10B) can be used for
-
Ab176092-5mgLexatumumab (anti-TNFRSF10B) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab (anti-TNFRSF10B) induces apoptosis in malignant mesothelioma. Lexatumumab (anti-TNFRSF10B) can be used for
-
Ab170779-100μgLorvotuzumab (anti-CD56) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab (anti-CD56) can be used to synthesize an ADC compound, Lorvotuzumab mertansine.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg